Email updates

Keep up to date with the latest news and content from BMC Medical Genetics and BioMed Central.

Open Access Research article

No evidence for association between SLC11A1 and visceral leishmaniasis in India

Sanjana Mehrotra12, Joyce Oommen2, Anshuman Mishra1, Medhavi Sudharshan1, Puja Tiwary1, Sarra E Jamieson2, Michaela Fakiola23, Deepa Selvi Rani4, Kumarasamy Thangaraj4, Madhukar Rai1, Shyam Sundar1 and Jenefer M Blackwell23*

  • * Corresponding author: Jenefer M Blackwell jmb37@cam.ac.uk

  • † Equal contributors

Author Affiliations

1 Institute of Medical Sciences, Banaras Hindu University, Varanasi, OS 221 005, India

2 Telethon Institute for Child Health Research, Centre for Child Health Research, The University of Western Australia, Subiaco, Western Australia, Australia

3 Cambridge Institute for Medical Research and Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge, UK

4 Centre for Cellular and Molecular Biology, Hyderabad, India

For all author emails, please log on.

BMC Medical Genetics 2011, 12:71  doi:10.1186/1471-2350-12-71

The electronic version of this article is the complete one and can be found online at: http://www.biomedcentral.com/1471-2350/12/71


Received:22 February 2011
Accepted:20 May 2011
Published:20 May 2011

© 2011 Mehrotra et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background

SLC11A1 has pleiotropic effects on macrophage function and remains a strong candidate for infectious disease susceptibility. 5' and/or 3' polymorphisms have been associated with tuberculosis, leprosy, and visceral leishmaniasis (VL). Most studies undertaken to date were under-powered, and none has been replicated within a population. Association with tuberculosis has replicated variably across populations. Here we investigate SLC11A1 and VL in India.

Methods

Nine polymorphisms (rs34448891, rs7573065, rs2276631, rs3731865, rs17221959, rs2279015, rs17235409, rs17235416, rs17229009) that tag linkage disequilibrium blocks across SLC11A1 were genotyped in primary family-based (313 cases; 176 families) and replication (941 cases; 992 controls) samples. Family- and population-based analyses were performed to look for association between SLC11A1 variants and VL. Quantitative RT/PCR was used to compare SLC11A1 expression in mRNA from paired splenic aspirates taken before and after treatment from 24 VL patients carrying different genotypes at the functional promoter GTn polymorphism (rs34448891).

Results

No associations were observed between VL and polymorphisms at SLC11A1 that were either robust to correction for multiple testing or replicated across primary and replication samples. No differences in expression of SLC11A1 were observed when comparing pre- and post-treatment samples, or between individuals carrying different genotypes at the GTn repeat.

Conclusions

This is the first well-powered study of SLC11A1 as a candidate for VL, which we conclude does not have a major role in regulating VL susceptibility in India.

Keywords:
SLC11A1; visceral leishmaniasis; genetic susceptibility

Background

Visceral leishmaniasis (VL) is a debilitating vector borne disease caused by parasites of the Leishmania donovani complex. Prevalence is high in Bihar State in India, indicating a need to understand more about disease pathogenesis to facilitate disease control. Population based epidemiological surveys suggest that 80-90% of individuals infected with L. donovani show no clinical symptoms [1,2]. Familial clustering, and the range of clinical outcomes from asymptomatic to fatal disease within and between ethnic groups sharing similar risk factors in Brazil [3,4] and Sudan [5,6], support a contribution of host genotype to susceptibility. Candidate gene and genome-wide linkage studies have highlighted a number of genes/gene regions contributing to disease susceptibility (reviewed [7]). However, replication between study sites has not been observed possibly due to small samples size and limited statistical power.

Amongst the genes studied to date, the most compelling candidate for VL susceptibility is SLC11A1 (formerly NRAMP1). SLC11A1 encodes solute carrier family 11a member 1, a transporter that regulates divalent cation homeostasis in macrophages and has many pleiotropic effects on macrophage activation (reviewed [8,9]). The gene was first identified for its role in controlling Leishmania donovani (gene designation Lsh), Salmonella typhimurium (Ity) and Mycobacterium bovis (Bcg) infections in mice [8,9]. The positionally cloned [10] candidate for these 3 genes was designated as the natural resistance associated macrophage protein 1 (Nramp1) for a period before its specific function as a transporter was confirmed [11]. In mice, susceptibility to infection is associated with a coding region mutation in transmembrane domain 4 of Slc11a1 [10]. In humans, no functional coding region variants have been identified [12], but common alleles 2 [T(GT)5AC(GT)5AC(GT)10] and 3 [T(GT)5AC(GT)5AC(GT)9] of a functional [13] Z-DNA forming GTn repeat (rs34448891) in the promoter region have been associated with disease risk, or protection from, a number of autoimmune and infectious diseases (reviewed [8,14]). Amongst these associations, a common theme was risk of autoimmune disease with allele 3 which drives higher SLC11A1 expression and pro-inflammatory cytokine production by macrophages, while the lower expressing allele 2 was associated with anti-inflammatory cytokines and infectious disease susceptibility, including tuberculosis [15]. In contrast, in Sudan the proinflammatory GTn repeat allele 3 is on a risk haplotype for VL caused by L. donovani that includes variants at single nucleotide polymorphisms (SNPs) designated 274C/T in exon 3 (rs2276631) and 469 + 14G/C in intron 4 (rs3731865) in the 5' region of the gene [12]. This was interpreted in relation to VL pathology which is associated with a strong pro-inflammatory tumour necrosis factor alpha response [16]. In some populations infectious disease association (listed in additional on-line tables in reference [17]) has been with 3' variants at SLC11A1 rather than, or in addition to, the 5' polymorphic loci, including two insertion/deletion (IN/DEL) polymorphisms TGTG/- (rs17235416) and CAAA/- (rs17229009) in the 3'UTR. The latter are potentially regulatory polymorphisms, although this has not been demonstrated experimentally. Here we report on well-powered two-stage primary family-based, followed by a replication population-based, genetic association study that fails to support either a role for polymorphism at SLC11A1 in determining susceptibility to VL caused by L. donovani in India, or for the GTn repeat polymorphism in determining mRNA expression levels of SLC11A1 in splenic aspirates from VL patients before or after chemotherapy.

Methods

The study was conducted in the district of Muzaffarpur in Bihar State, India, where VL is highly endemic. VL cases and family members or controls were from villages located within a radius of ~100 km from the city of Muzaffarpur covering the districts of Muzaffarpur, Vaishali, Samastipur, Saran, Sheohar, East Champaran and Sitamarhi. Initially, families with at least two siblings affected with clinical VL were ascertained from medical records held in the Kala-Azar Medical Research Centre (KAMRC) in Muzaffarpur, India [18]. This was later extended to collection of singleton cases plus parent (trios) (see Table 1A). The replication study comprised 958 unrelated cases and 1015 unrelated controls. The controls had no history of VL, or a family history of VL among first-, second- or third-degree relatives. Patients and controls were matched for self-reported age, sex, religion, caste and geographic district of recruitment (see Table 1B). Diagnosis of VL was based on presence of typical clinical features of VL i.e. fever with rigors and chills, splenomegaly, weight loss and pancytopenia followed by demonstration of parasites by parasitological methods (light microscopy, in vitro culture) using splenic aspirates [19]. Additional VL cases identified in the field were confirmed on the basis of proof of medical records of diagnosis and treatment issued from one of the local health clinics or private practice, and accompanied by demonstration of clinical response to anti-leishmanial treatment (typically with amphotericin B). An annual incidence rate of 2.49 clinical VL cases/1,000 persons has been reported in the region [20]. L. donovani sensu strictu (zymodeme MON-2) was confirmed as the causative agent of VL in the study region, in accordance with other reports on clinical isolates from kala-azar patients in the state of Bihar [21-24]. Additional epidemiological and demographic details relating to the study site are described elsewhere [25]. Informed written consent in Hindi was obtained from all participating individuals and from parents of children under 18 years old. Approval for the study was provided by the Ethical Committee of the Institute of Medical Sciences, Banaras Hindu University, Varanasi, India. Collection of families for the primary study was undertaken between 2004 and 2006. The replication study collection was undertaken during 2009-2010. For the family-based primary study DNA was prepared from buccal swabs by whole genome amplification as described [18], and SNPs genotyped using ABI predesigned Taqman assays (ABI, Mulgrave, Victoria, Australia). For the replication case-control study, genomic DNA was extracted from saliva using the Oragene technology (DNA Genotek, Ontario, Canada), and SNPs genotyped using Sequenom iPLEX platform (Sequenom, San Diego, CA). The GTn repeat and IN/DELS were genotyped for all samples using ABI fragment analysis processed on an ABI3130 (Australia) or ABI3730 (India) Genetic Analyser.

Table 1. Baseline characteristics of (A) families for the primary sample of Indian multicase VL families, and (B) the Indian case-control cohorts.

Family-based allelic association tests based on the TDT but generalized to allow analysis under additive and genotype-wise models of inheritance were performed within FBAT under the null hypothesis of "no linkage and no association" [26,27]. TDT power approximations [28] show that the 313 primary VL trios had ≥95% power to detect an odds ratio ≥2 at P = 0.01 for markers with MAF ≥ 0.1, but only 49% power for an odds ratio of 1.5. Nevertheless, our primary sample was well-powered to detect effect sizes (odds ratios ≥ 2) equivalent to those observed in the earlier study of SLC11A1 and VL in Sudan [12]. Robust association tests were performed to take account of multiple trios within a pedigree. Association tests for the replication case-control sample were undertaken using logistic regression analysis performed in PLINK [29] or LOGIT (Stata) using an additive model and a genotypic test. The 941 cases and 992 controls which passed quality control (Hardy-Weinberg Equilibrium) had 100% power to detect associations with an odds ratio of 2 for markers with MAF ≥ 0.1 at P = 0.001, and 93.5% power for odds ratio 1.5; MAF ≥ 0.1, P = 0.01.

Splenic biopsies were taken as part of routine diagnostic procedure at the Kala Azar Medical Research Centre, Muzaffarpur, Bihar State, India. Since the spleen is a major focus for parasite growth inside macrophages, this afforded an important opportunity to analyse gene expression in a primary site of infection. Pre- and post- treated patient's splenic samples were collected in 5 × RNA Later (Ambion) during 2009-2010, transported to Varanasi at 4°C and stored at -80°C until RNA was isolated. Details regarding age and sex (15 males, median age 16, range 7 to 45 years; 9 females, median age 10, range 8 to 30 years) splenic parasites (21 confirmed positive; 3 not done) and drug administered (19 Miltefosine; 1 Miltefosine + Paramomycin; 1Ambisome + Paramomycin; 3Amphomul) were recorded for each patient. Total RNA was isolated using RNeasy tissue kit (Qiagen) according to the manufacturer's instructions and eluted in 30 ul of RNase free water. Sample quality and integrity was assessed by ND-2000 spectrophotometer (Thermo Fischer Scientific) and agarose (Sigma Aldrich) gel electrophoresis. 500 ng of RNA was reverse transcribed using the High Capacity cDNA synthesis kit (Applied Biosystems). Taqman predesigned gene expression assay (Hs00184453_m1) was used to perform expression studies (7500 HT Real Time PCR system, ABI, Foster City CA, USA) with 18S rRNA (P/N 4319413E) used as an endogenous control to normalize the expression data. Experiments were performed on 24 paired pre- and post-treatment splenic aspirates from VL patients with appropriate no RT and no template controls included in each plate. All samples were run in duplicate. Results were analysed by 7500 software v.2.0.1 and Graph pad prism 5. Paired Student's T tests was used to test for significant differences between pre (Day-0) and post (D-30) expression levels for each genotype, i.e. 3/3, 3/2 and 2/2. One way ANOVA was used to test for differences between 3/3 vs 3/2 vs 2/2 groups at either Day-0 or Day-30.

Results and Discussion

To undertake our study we initially genotyped 9 polymorphisms (Table 2) in 176 nuclear families (Table 1) used in our previous study [18] that contain 313 offspring with VL collected in the area of Muzaffarpur, Bihar State, India, where L. donovani is endemic. This included the putative functional 5' GTn repeat and 3'UTR TGTG/- and CAAA/- IN/DELs, as well as the exon 3 274C/T (rs2276631) and intron 4 469 + 14G/C (rs3731865) SNPs shown to be associated with VL in Sudan [12]. Using the family-based association test (FBAT) [30,31] in this primary family dataset (Table 3) we found tentative evidence (nominal P-values ≤0.05) for associations between VL and 5' GTn repeat, and between VL and the 3'UTR CAAA/- IN/DEL. In particular (Table 3B), homozygosity for the high expressing pro-inflammatory allele 3 at the GTn repeat was associated with disease (Z-score = +2.382; nominal P = 0.017), while homozygosity for allele 2 (the deletion) was associated with protection for the 3'UTR CAAA IN/DEL (Z-score = -2.332; nominal P = 0.019). Since these two markers are not in strong LD with each other (Additional Figure 1: D' = 0.52; r2 = 0.16), these associations are likely to be independent, if real. Neither association is robust to application of a strict Bonferroni correction for 9 SNPs genotyped, which requires a significance cut-off of P ≤ 0.006 (i.e. P = 0.05/9). Given that the 8 SNPs that passed quality control are not all independent (Additional Figure 1), this is over-conservative. A less stringent correction taking account of non-independence of markers provides a cut-off of P ≤ 0.017 (i.e. P = 0.05/3; 2 LD blocks plus 1 independent marker).

Table 2. Details of polymorphisms genotyped and the minor allele frequency (MAF) of variants in the Indian study population.

Table 3. Family-based association analysis between SLC11A1 and VL

Additional File 1. Figure S1. Haploview analysis for D' and r2 pairwise measures of linkage disequilibrium between SLC11A1 polymorphisms in the control sample for the replication sample from India.

Format: PDF Size: 65KB Download file

This file can be viewed with: Adobe Acrobat ReaderOpen Data

Suggestive evidence for an association between Indian VL and allele 3 at the functional promoter region GTn polymorphism at SLC11A1, which was consistent with data for VL from Sudan [12], prompted us to pursue two further avenues of investigation. First, we looked at expression levels of SLC11A1 in mRNA from splenic aspirates from patients carrying the 3 different genotypes at the GTn repeat (Figure 1). This failed to show any significant differences in expression levels of SLC11A1 in splenic aspirates from VL patients carrying the three GTn genotypes, either before or after treatment, as determined using one way ANOVA. Nor were there differences in expression within each genotype when pre- and post-treatment values were compared using paired Student's T tests. This suggests that differences in expression levels driven by the GTn repeat in luciferase assays in vitro, especially under lipopolysaccharide and interferon-γ stimulation [13,32], do not necessarily translate into regulation of expression in VL infected spleens in vivo. Secondly, we carried out a comprehensive replication of the association study in a much larger population-based case-control sample from the same region of Bihar State in India (Table 4). This study failed to show association between VL and any of the 8 markers that passed quality control. The trend for genotypic association at the GTn was in the reverse direction (i.e. a3 was the risk allele in the primary sample, and the protective allele in the replication samples) to that seen in the primary analysis (Table 3). Analyses using caste, which we have shown to provide a good surrogate for population substructure in genome-wide analyses (unpublished data), or religion as covariates also failed to provide evidence for positive associations in the case-control analysis (data not shown).

Table 4. Population-based association analysis between SLC11A1 and VL

thumbnailFigure 1. Relative expression of SLC11A1 mRNA in splenic aspirates from VL patients (A) before (Day 0), and (B) after (Day 30), antileishmanial treatment. Data are shown according to genotype (3/3, 2/3, 2/2) at the SLC11A1 GTn promoter repeat polymorphism. Values represent mean ± SEM. Paired Student's T test showed no significant differences in expression of SLC11A1 when D0 values were compared to D30 valules for each genotype. No differences between genotypes were observed at either D0 or D30 as deteremined by one way ANOVA.

Here we re-examined SLC11A1 as a candidate gene for susceptibility to VL in India. Despite preliminary evidence for a role for putative functional polymorphisms in the 5' promoter and 3'UTR regions, we were unable to find supporting evidence for this in functional studies or in a large, well-powered, replication sample for association analysis. We conclude that SLC11A1 does not play a major role in determining susceptibility to VL in India. These results also call into question the earlier association observed between VL and SLC11A1 in Sudan [12], which was based on a single small sample of families. Whilst this could represent genetic heterogeneity between human populations and/or the parasite, it is also possible that this first report of association in humans could be a case of beginner's curse. Results presented here suggest that associations observed in small-scale primary samples require validation to determine whether they remain true for the population in which they have been observed.

Conclusions

This is the first well-powered study of SLC11A1 as a candidate for VL, which we conclude does have a major role in regulating VL susceptibility in India.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

AM, MF and SM carried out the field collection and/or preparation of the samples. SM and JO performed the genotyping, and participated in the statistical analysis and interpretation of the data. SEJ trained SM in the laboratory for genotyping techniques, in database entry and use of the genetic database GenIE in Perth, and in genetic statistical analysis methods. MF cross-checked statistical analyses and carried out additional statistical tests. MR oversaw laboratory-based work in Varanasi. DSR and KT oversaw the Sequenom genotyping undertaken by SM in Hyderabad. MS and PT assisted with RNA preparation. SM designed and carried out the QRT/PCR. SS helped conceive the study, was responsible for clinical care of cases at the Kala Azar Medical Research Centre, Muzaffarpur, Bihar State, India, and provided the logistical support to make the study possible. SM prepared the first draft of the manuscript. JMB designed the study, conceived the specific hypothesis to be tested, made the final interpretation of the data, and prepared the final manuscript. All authors read and approved the final manuscript.

Acknowledgements

We would like to thank the families from the state of Bihar, northeast India for their participation in this study. The authors declare no conflict of interest. This research was funded by grants from The Wellcome Trust in the UK (grant numbers: 074196/Z/04/Z and 085475/Z/08/Z) and The National Institutes for Health in the USA (grant numbers: R01 AI076233-01 and 1P50AI074321-01).

References

  1. Desjeux P: The increase in risk factors for leishmaniasis worldwide.

    Trans R Soc Trop Med Hyg 2001, 95(3):239-243. PubMed Abstract | Publisher Full Text OpenURL

  2. Badaro R, Jones TC, Lorenco R, Cerf BJ, Sampaio D, Carvalho EM, Rocha H, Teixeira R, Johnson WD Jr: A prospective study of visceral leishmaniasis in an endemic area of Brazil.

    J Infect Dis 1986, 154(4):639-649. PubMed Abstract | Publisher Full Text OpenURL

  3. Peacock CS, Collins A, Shaw MA, Silveira F, Costa J, Coste CH, Nascimento MD, Siddiqui R, Shaw JJ, Blackwell JM: Genetic epidemiology of visceral leishmaniasis in northeastern Brazil.

    Genet Epidemiol 2001, 20(3):383-396. PubMed Abstract | Publisher Full Text OpenURL

  4. Cabello PH, Lima AM, Azevedo ES, Krieger H: Familial aggregation of Leishmania chagasi infection in northeastern Brazil.

    Am J Trop Med Hyg 1995, 52(4):364-365. PubMed Abstract | Publisher Full Text OpenURL

  5. Zijlstra EE, el-Hassan AM, Ismael A, Ghalib HW: Endemic kala-azar in eastern Sudan: a longitudinal study on the incidence of clinical and subclinical infection and post-kala-azar dermal leishmaniasis.

    Am J Trop Med Hyg 1994, 51(6):826-836. PubMed Abstract | Publisher Full Text OpenURL

  6. Blackwell JM, Mohamed HS, Ibrahim ME: Genetics and visceral leishmaniasis in the Sudan: seeking a link.

    Trends Parasitol 2004, 20(6):268-274. PubMed Abstract | Publisher Full Text OpenURL

  7. Blackwell JM, Fakiola M, Ibrahim ME, Jamieson SE, Jeronimo SB, Miller EN, Mishra A, Mohamed HS, Peacock CS, Raju M, Sundar S, Wilson ME: Genetics and visceral leishmaniasis: of mice and man.

    Parasite Immunol 2009, 31(5):254-266. PubMed Abstract | Publisher Full Text OpenURL

  8. Blackwell JM, Goswami T, Evans CAW, Sibthorpe D, Papo N, White JK, Searle S, Miller EN, Peacock CS, Mohammed H, Ibrahim M: SLC11A1 (formerly NRAMP1) and disease.

    Cell Microbiol 2001, 3:773-784. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  9. Blackwell JM, Searle S, Mohamed H, White JK: Divalent cation transport and susceptibility to infectious and autoimmune disease: continuation of the Ity/Lsh/Bcg/Nramp1/Slc11a1 gene story.

    Immunol Lett 2003, 85(2):197-203. PubMed Abstract | Publisher Full Text OpenURL

  10. Vidal SM, Malo D, Vogan K, Skamene E, Gros P: Natural resistance to infection with intracellular parasites: isolation of a candidate for Bcg.

    Cell 1993, 73:469-485. PubMed Abstract | Publisher Full Text OpenURL

  11. Goswami T, Bhattacharjee A, Babal P, Searle S, Moore E, Li M, Blackwell JM: Natural-resistance-associated macrophage protein 1 is an H+/bivalent cation antiporter.

    Biochem J 2001, 354(Pt 3):511-519. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  12. Mohamed HS, Ibrahim ME, Miller EN, White JK, Cordell HJ, Howson JMM, Peacock CS, Khalil EAG, Elhassan AM, Blackwell JM: SLC11A1 (formerly NRAMP1) and susceptibility to visceral leishmaniasis in The Sudan.

    Eur J Hum Genet 2004, 12:66-74. PubMed Abstract | Publisher Full Text OpenURL

  13. Searle S, Blackwell JM: Evidence for a functional repeat polymorphism in the promoter of the human NRAMP1 gene that correlates with autoimmune versus infectious disease susceptibility.

    J Med Genet 1999, 36(4):295-299. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  14. Blackwell JM, Jiang HR, White JK: Role of Nramp family in pro-inflammatory diseases. In The Nramp Family. Edited by Cellier MFM, Gros P. Kluwer Academic/Landes, New York, NY; 2004:53-64. OpenURL

  15. Awomoyi AA, Marchant A, Howson JM, McAdam KP, Blackwell JM, Newport MJ: Interleukin-10, polymorphism in SLC11A1 (formerly NRAMP1), and susceptibility to tuberculosis.

    J Infect Dis 2002, 186:1804-1814. OpenURL

  16. Barral-Netto M, Badaro R, Barral A, Almeida RP, Santos SB, Badaro F, Pedral-Sampaio D, Carvalho EM, Falcoff E, Falcoff R: Tumor necrosis factor (cachectin) in human visceral leishmaniasis.

    J Infect Dis 1991, 163:853-857. PubMed Abstract | Publisher Full Text OpenURL

  17. Burgner D, Jamieson SE, Blackwell JM: Genetic susceptibility to infectious diseases: big is beautiful, but will bigger be even better?

    Lancet Infect Dis 2006, 6(10):653-663. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  18. Fakiola M, Mishra A, Rai M, Singh SP, O'Leary RA, Ball S, Francis RW, Firth MJ, Radford BT, Miller EN, Sundar S, Blackwell JM: Classification and regression tree and spatial analyses reveal geographic heterogeneity in genome wide linkage study of Indian visceral leishmaniasis.

    PLoS ONE 2010, 5(12):e15807. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  19. Sundar S, Benjamin B: Diagnosis and treatment of Indian visceral sleishmaniasis.

    J Assoc Physicians India 2003, 51:195-201. PubMed Abstract OpenURL

  20. Singh SP, Reddy DC, Rai M, Sundar S: Serious underreporting of visceral leishmaniasis through passive case reporting in Bihar, India.

    Trop Med Int Health 2006, 11(6):899-905. PubMed Abstract | Publisher Full Text OpenURL

  21. Manna M, Majumder HK, Sundar S, Bhaduri AN: The molecular characterization of clinical isolates from Indian Kala-azar patients by MLEE and RAPD-PCR.

    Med Sci Monit 2005, 11(7):BR220-227. PubMed Abstract | Publisher Full Text OpenURL

  22. Sundar S, Pai K, Kumar R, Pathak-Tripathi K, Gam AA, Ray M, Kenney RT: Resistance to treatment in Kala-azar: speciation of isolates from northeast India.

    Am J Trop Med Hyg 2001, 65(3):193-196. PubMed Abstract | Publisher Full Text OpenURL

  23. Thakur CP, Dedet JP, Narain S, Pratlong F: Leishmania species, drug unresponsiveness and visceral leishmaniasis in Bihar, India.

    Trans R Soc Trop Med Hyg 2001, 95(2):187-189. PubMed Abstract | Publisher Full Text OpenURL

  24. Chatterjee M, Manna M, Bhaduri AN, Sarkar D: Recent kala-azar cases in India: isozyme profiles of Leishmania parasites.

    Indian J Med Res 1995, 102:165-172. PubMed Abstract OpenURL

  25. Singh SP, Reddy DC, Mishra RN, Sundar S: Knowledge, attitude, and practices related to Kala-azar in a rural area of Bihar state, India.

    Am J Trop Med Hyg 2006, 75(3):505-508. PubMed Abstract | Publisher Full Text OpenURL

  26. Laird NM, Horvath S, Xu X: Implementing a unified approach to family-based tests of association.

    Genet Epidemiol 2000, 19(Suppl 1):S36-42. PubMed Abstract OpenURL

  27. Horvath S, Xu X, Laird NM: The family based association test method: strategies for studying general genotype--phenotype associations.

    Eur J Hum Genet 2001, 9(4):301-306. PubMed Abstract | Publisher Full Text OpenURL

  28. Knapp M: A note on power approximations for the transmission disequilibrium test.

    Am J Hum Genet 1999, 64(4):1177-1185. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  29. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham PC: PLINK: a tool set for whole-genome association and population-based linkage analyses.

    Am J Hum Genet 2007, 81(3):559-575. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  30. Laird NM, Horvath S, Xu X: Implementing a unified approach to family-based tests of association.

    Genet Epidemiol 2000, 19(Suppl 1):S36-42. PubMed Abstract OpenURL

  31. Horvath S, Xu X, Laird NM: The family based association test method: strategies for studying general genotype--phenotype associations.

    Eur J Hum Genet 2001, 9(4):301-306. PubMed Abstract | Publisher Full Text OpenURL

  32. Zaahl MG, Robson KJ, Warnich L, Kotze MJ: Expression of the SLC11A1 (NRAMP1) 5'-(GT)n repeat: opposite effect in the presence of -237C-->T.

    Blood Cells Mol Dis 2004, 33(1):45-50. PubMed Abstract | Publisher Full Text OpenURL

  33. Liu J, Fujiwara TM, Buu NT, Sanchez FO, Cellier M, Paradis AJ, Frappier D, Skamene E, Gros P, Morgan K, Schurr E: Identification of polymorphisms and sequence variants in human homologue of the mouse natural resistance-associated macrophage protein gene.

    Am J Hum Genet 1995, 56:845-853. PubMed Abstract | PubMed Central Full Text OpenURL

  34. Clayton DG, Walker NM, Smyth DJ, Pask R, Cooper JD, Maier LM, Smink LJ, Lam AC, Ovington NR, Stevens HE, Nutland S, Howson JM, Faham M, Moorhead M, Jones HB, Falkowski M, Hardenbol P, Willis TD, Todd JA: Population structure, differential bias and genomic control in a large-scale, case-control association study.

    Nat Genet 2005, 37(11):1243-1246. PubMed Abstract | Publisher Full Text OpenURL

Pre-publication history

The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-2350/12/71/prepub